|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Chromogranin A mRNA, which codes for the major secretory granule protein, was present in 25/26 tumors including all tumors that were negative for pituitary hormone mRNAs, indicating adequate preservation of specific mRNA transcripts in the paraffin-embedded sections of tumor cells.
|
1653518 |
1991 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The tumor manifested several features that were consistent with pancreatic neuroendocrine tumors (panNETs), such as organoid structures with trabecular and cribriform patterns, and the expression of chromogranin A and synaptophysin.
|
26192435 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Age [hazard ratio (HR) 1.0, p < 0.001), small bowel primary site (HR 0.5, p < 0.001), hepatic resection (HR 0.3, p = 0.001), well-differentiated tumors (HR 0.3, p < 0.001), alkaline phosphatase within normal limit (WNL) (HR 0.4, p < 0.001), and chromogranin A WNL (HR 0.5, p < 0.001) were significant independent prognosticators for OS.
|
28303430 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
AdVince includes the gene promoter from human chromogranin A for selective replication in neuroendocrine cells, miR122 target sequences for reduced liver toxicity, and a cell-penetrating peptide in the capsid for increased infectivity of tumor cells and optimized spread within tumors.
|
27442441 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SIGNIFICANCE: This work reveals that the interaction between fragmented chromogranin A and neuropilin-1 is required for tumor growth and represents a novel potential therapeutic target.
|
30796053 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Biopsy of the tumors revealed paraganglioma with chromogranin A-immunopositive cells.
|
19415531 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We can conclude that plasma CGA concentration as determined by radioimmunometric assay (which is simple without the necessity of special laboratory equipment) is an effective marker of pheochromocytoma with association to malignity and tumor mass.
|
18271679 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To investigate, at the molecular level, the mechanisms leading to NB tumour cell differentiation during the treatment with biologically active compounds, we sequenced and functionally characterised 2169 bp of a genomic DNA clone encompassing the 5' flanking region of the human CHGA gene.
|
7576943 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our study demonstrated that integration of proteomics and transcriptomics could prove advantageous for accelerating tumor biomarker discovery and CHGA and CLU might be important novel biomarkers and therapeutic targets for invasion of NFPAs.
|
26753958 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
No significant correlation between CgA and tumor diameter was found (P = 0.057).
|
30470614 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, the opposing effects of the CgA-derived vasostatin-I and catestatin and the SgII-derived peptide SN on the integrity of the vasculature, myocardial contractility, angiogenesis in wound healing, inflammatory conditions and tumors will be discussed.
|
28442394 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
By RT-PCR, CgA mRNA was found in 20 cases (50 per cent), including the five tumours positive by IHC.
|
9924430 |
1998 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Quantitative reverse transcriptase polymerase chain reaction (Q RT-PCR) gene expression was quantified against glyseraldehyde-3-phosphate dehydrogenase (GAPDH) and CgA and MTA1 protein expression levels were analyzed by immunohistochemical analyses of a gastric neoplasia microarray.
|
16502410 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
No association was observed between serum CgA levels and tumour grade (G1, G2 and G3), but serum CgA levels differed significantly between patients with GEP-NENs of different origins (P<0.05).
|
30675205 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients with SCCC have poor prognosis.FIGO stage, tumor mass size and CgA stained positive may act as a surrogate for factors prognostic of survival.
|
22529895 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms.
|
29633144 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Six months of treatment with sunitinib was associated with normalization of the patient's performance status and blood pressure, absence of symptoms of catecholamine excess, weight gain, disappearance of pain, shrinkage of each of the tumors (50% in the largest renal tumor, 38% in the largest islet cell tumor, 21% in the pelvic malignant pheochromocytoma), and reduction of plasma normetanephrines and chromogranin A.
|
19017755 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumour was positive for adrenocorticotropic hormone, chromogranin A (CGA), and steroidogenic factor-1 (SF-1) on the tumour surface.
|
28193212 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms: Is It Really Game Over? A Systematic Review and Meta-analysis.
|
30325865 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame.
|
29066503 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Plasma CgA level was significantly associated with the size (P=0.03), metastasis (P=0.02) and tumor stage (P=0.03) of the PNETs.
|
29805630 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the nomogram was not universally applicable as even at our specialty center, variables such as chromogranin A and urinary 5-hydroxyindoleacetic acid are not routinely collected, whereas others, like tumor grade, do not reflect the most recently updated classifications.
|
30946234 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry with antibodies against chromogranin A (CgA), synaptophysin and CCKBR, and in situ hybridization with probes against CgA, CCKBR and histidine decarboxylase were used to further explore these tumors.
|
28980157 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CYFRA 21.1 (p < 0.001, r = 0.394), HE4 (p = 0.014, r = 0.279) and CgA (p = 0.023, r = 0.259) levels were positively correlated with tumor stage in NSCLC.
|
29729229 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Patients' IL-2 serum levels were compared to IL-2 -330 T/G genotypes and tumor functional status and finally with known markers such as chromogranin A (CgA) and 5-hydroxyindolacetic acid (5-HIAA).
|
20049409 |
2010 |